{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:36Z","timestamp":1792075536772,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer is known to have a cold tumor microenvironment (TME) that promotes immune evasion through different cellular pathways. Aggressive disease progression is often linked to Regulatory T cells (Tregs) which play an important role in immunosuppression. While immunotherapy aims to use the immune system to fight tumor cells, its efficacy is frequently hindered by Tregs, which prevent effector T cells from reaching and fighting tumor cells. This review evaluates the impact of different immunotherapeutic interventions, alone or in combination, on Treg frequency and function within the prostate TME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines, a systematic search of major databases identified studies investigating immunotherapeutic effects on Tregs in prostate cancer. Studies were included if they evaluated monotherapies or combination strategies, as defined by inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>31 studies met the inclusion criteria. Qualitative analysis revealed that monotherapies, including immune checkpoint inhibitors and vaccines, produced inconsistent effects on Treg populations, which in many cases did not significantly decrease their levels or suppressive function. Notable exceptions included targeted recruitment inhibitors such as anti-CCR4 and specific viral-mediated therapies. In contrast, combination therapies proved to be more effective in reshaping the TME. When immunotherapy and other treatment such as androgen deprivation therapy, immunogenic chemotherapy, and targeted molecular inhibition are combined, enhanced anti-tumor immunity is observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Successful modulation of the prostate TME requires shifting from monotherapy toward combination strategies that overcome Treg-mediated immunosuppression. Effector-to-Treg ratios and functional markers, rather than Treg frequency alone, may better predict outcomes, as CD8\u207a infiltration does not always reflect restored cytotoxicity. These findings highlight the dual potential of Tregs as therapeutic targets and biomarkers in prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16550-w","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:53:54Z","timestamp":1784274834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of immunotherapy as a monotherapy or in combination with conventional therapies on regulatory T-cell (Treg) modulation in prostate cancer: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4948-3651","authenticated-orcid":false,"given":"Olayemi Oluseun","family":"Akinnola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2972-9149","authenticated-orcid":false,"given":"Ayomide Iyanuoluwa","family":"Olaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3787-1112","authenticated-orcid":false,"given":"Barnabas Adeoluwa","family":"Adejoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-5555","authenticated-orcid":false,"given":"Abimbola David","family":"Akinyosoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"16550_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"16550_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2147\/CMAR.S189893","volume":"11","author":"W Huang","year":"2019","unstructured":"Huang W, Zhang Y, Shen B-H, et al. Outcomes of health-related quality of life after open, laparoscopic, or robot-assisted radical prostatectomy in China. CMAR Volume. 2019;11:899\u2013907. https:\/\/doi.org\/10.2147\/CMAR.S189893.","journal-title":"CMAR Volume"},{"key":"16550_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.15698\/mic2022.12.787","volume":"9","author":"S Terrisse","year":"2022","unstructured":"Terrisse S, Zitvogel L, Kroemer G. Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy. Microb Cell. 2022;9:190\u20134. https:\/\/doi.org\/10.15698\/mic2022.12.787.","journal-title":"Microb Cell"},{"key":"16550_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N. Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management. Curr Treat Options Oncol. 2024;25:914\u201331. https:\/\/doi.org\/10.1007\/s11864-024-01215-2.","journal-title":"Curr Treat Options Oncol"},{"key":"16550_CR5","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.3390\/cancers17213441","volume":"17","author":"J Huang","year":"2025","unstructured":"Huang J, Ojo A, Tsao S, et al. Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment Outcomes. Cancers. 2025;17:3441. https:\/\/doi.org\/10.3390\/cancers17213441.","journal-title":"Cancers"},{"key":"16550_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41391-024-00825-z","volume":"28","author":"B Fang","year":"2025","unstructured":"Fang B, Lu Y, Li X, et al. Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer. Prostate Cancer Prostatic Dis. 2025;28:260\u20139. https:\/\/doi.org\/10.1038\/s41391-024-00825-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16550_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21147\/j.issn.1000-9604.2025.01.07","volume":"37","author":"T Ding","year":"2025","unstructured":"Ding T, He L, Lin G, et al. Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer. Chin J Cancer Res. 2025;37:90\u2013114. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.01.07.","journal-title":"Chin J Cancer Res"},{"key":"16550_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","volume":"11","author":"D-C Feng","year":"2024","unstructured":"Feng D-C, Zhu W-Z, Wang J, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Military Med Res. 2024;11:21. https:\/\/doi.org\/10.1186\/s40779-024-00526-7.","journal-title":"Military Med Res"},{"key":"16550_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","volume":"80","author":"H-R Cha","year":"2020","unstructured":"Cha H-R, Lee JH, Ponnazhagan S. Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Res. 2020;80:1615\u201323. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2948.","journal-title":"Cancer Res"},{"key":"16550_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.22465\/juo.234600100005","volume":"21","author":"JE Kim","year":"2023","unstructured":"Kim JE, Lee K, Kim IY. Current Update on Prostate Cancer Immunotherapy. Korean J Urol Oncol. 2023;21:14\u201322. https:\/\/doi.org\/10.22465\/juo.234600100005.","journal-title":"Korean J Urol Oncol"},{"key":"16550_CR11","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/cancers17071064","volume":"17","author":"W-A Kwon","year":"2025","unstructured":"Kwon W-A, Joung JY. Immunotherapy in Prostate Cancer: From a Cold Tumor to a Hot. Prospect Cancers. 2025;17:1064. https:\/\/doi.org\/10.3390\/cancers17071064.","journal-title":"Prospect Cancers"},{"key":"16550_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00262-022-03347-6","volume":"72","author":"B Fang","year":"2023","unstructured":"Fang B, Wei Y, Zeng H, et al. Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients. Cancer Immunol Immunother. 2023;72:1541\u201351. https:\/\/doi.org\/10.1007\/s00262-022-03347-6.","journal-title":"Cancer Immunol Immunother"},{"key":"16550_CR13","doi-asserted-by":"publisher","first-page":"750542","DOI":"10.3389\/fimmu.2021.750542","volume":"12","author":"P Grover","year":"2021","unstructured":"Grover P, Goel PN, Greene MI. Regulatory T Cells: Regulation of Identity and Function. Front Immunol. 2021;12:750542. https:\/\/doi.org\/10.3389\/fimmu.2021.750542.","journal-title":"Front Immunol"},{"key":"16550_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4161\/onci.1.2.18480","volume":"1","author":"E Zhao","year":"2012","unstructured":"Zhao E, Wang L, Dai J, et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. OncoImmunology. 2012;1:152\u201361. https:\/\/doi.org\/10.4161\/onci.1.2.18480.","journal-title":"OncoImmunology"},{"key":"16550_CR15","doi-asserted-by":"publisher","first-page":"119132","DOI":"10.1016\/j.lfs.2021.119132","volume":"284","author":"V Karpisheh","year":"2021","unstructured":"Karpisheh V, Mousavi SM, Naghavi Sheykholeslami P, et al. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sci. 2021;284:119132. https:\/\/doi.org\/10.1016\/j.lfs.2021.119132.","journal-title":"Life Sci"},{"key":"16550_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","volume":"22","author":"M Iglesias-Escudero","year":"2023","unstructured":"Iglesias-Escudero M, Arias-Gonz\u00e1lez N, Mart\u00ednez-C\u00e1ceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22:26. https:\/\/doi.org\/10.1186\/s12943-023-01714-0.","journal-title":"Mol Cancer"},{"key":"16550_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/nyas.13625","volume":"1417","author":"K Shitara","year":"2018","unstructured":"Shitara K, Nishikawa H. Regulatory T cells: a potential target in cancer immunotherapy. Ann N Y Acad Sci. 2018;1417:104\u201315. https:\/\/doi.org\/10.1111\/nyas.13625.","journal-title":"Ann N Y Acad Sci"},{"key":"16550_CR18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","volume":"13","author":"N Sobhani","year":"2021","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, et al. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers. 2021;13:1440. https:\/\/doi.org\/10.3390\/cancers13061440.","journal-title":"Cancers"},{"key":"16550_CR19","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","volume":"110","author":"Y Ohue","year":"2019","unstructured":"Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080\u20139. https:\/\/doi.org\/10.1111\/cas.14069.","journal-title":"Cancer Sci"},{"key":"16550_CR20","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2326-6066.CIR-18-0386","volume":"7","author":"E Sanseviero","year":"2019","unstructured":"Sanseviero E, O\u2019Brien EM, Karras JR, et al. Anti\u2013CTLA-4 Activates Intratumoral NK Cells and Combined with IL15\/IL15R\u03b1 Complexes Enhances Tumor Control. Cancer Immunol Res. 2019;7:1371\u201380. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0386.","journal-title":"Cancer Immunol Res"},{"key":"16550_CR21","doi-asserted-by":"publisher","first-page":"8437","DOI":"10.2147\/OTT.S221340","volume":"12","author":"J Cai","year":"2019","unstructured":"Cai J, Wang D, Zhang G, Guo X. The Role Of PD-1\/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy. OTT Volume. 2019;12:8437\u201345. https:\/\/doi.org\/10.2147\/OTT.S221340.","journal-title":"OTT Volume"},{"key":"16550_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","journal-title":"Syst Rev"},{"key":"16550_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, De Vries RB, et al. SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43. https:\/\/doi.org\/10.1186\/1471-2288-14-43.","journal-title":"BMC Med Res Methodol"},{"key":"16550_CR24","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"16550_CR25","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ i4919. 2016. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"16550_CR26","doi-asserted-by":"publisher","first-page":"eaba9772","DOI":"10.1126\/scitranslmed.aba9772","volume":"13","author":"Y-X Lin","year":"2021","unstructured":"Lin Y-X, Wang Y, Ding J, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med. 2021;13:eaba9772. https:\/\/doi.org\/10.1126\/scitranslmed.aba9772.","journal-title":"Sci Transl Med"},{"key":"16550_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s41467-018-03900-x","volume":"9","author":"JF Anker","year":"2018","unstructured":"Anker JF, Naseem AF, Mok H, et al. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9:1591. https:\/\/doi.org\/10.1038\/s41467-018-03900-x.","journal-title":"Nat Commun"},{"key":"16550_CR28","doi-asserted-by":"publisher","first-page":"e003731","DOI":"10.1136\/jitc-2021-003731","volume":"10","author":"S Maeda","year":"2022","unstructured":"Maeda S, Motegi T, Iio A, et al. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer. J Immunother Cancer. 2022;10:e003731. https:\/\/doi.org\/10.1136\/jitc-2021-003731.","journal-title":"J Immunother Cancer"},{"key":"16550_CR29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/vaccines9070786","volume":"9","author":"L Guo","year":"2021","unstructured":"Guo L, Xie H, Zhang Z, et al. Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer. Vaccines. 2021;9:786. https:\/\/doi.org\/10.3390\/vaccines9070786.","journal-title":"Vaccines"},{"key":"16550_CR30","unstructured":"Ruan H, Tao Z, Chen K. Flightless I homolog reverses neo-endocrine therapy resistance through PD-L1 mediated-immune evasion in prostate cancer."},{"key":"16550_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/cgt.2017.15","volume":"24","author":"K Fujita","year":"2017","unstructured":"Fujita K, Nakai Y, Kawashima A, et al. Phase I\/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients. Cancer Gene Ther. 2017;24:277\u201381. https:\/\/doi.org\/10.1038\/cgt.2017.15.","journal-title":"Cancer Gene Ther"},{"key":"16550_CR32","doi-asserted-by":"publisher","first-page":"109309","DOI":"10.1016\/j.celrep.2021.109309","volume":"36","author":"E Dodagatta-Marri","year":"2021","unstructured":"Dodagatta-Marri E, Ma H-Y, Liang B, et al. Integrin \u03b1v\u03b28 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Cell Rep. 2021;36:109309. https:\/\/doi.org\/10.1016\/j.celrep.2021.109309.","journal-title":"Cell Rep"},{"key":"16550_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13046-025-03352-4","volume":"44","author":"AM Gasparri","year":"2025","unstructured":"Gasparri AM, Pocaterra A, Colombo B, et al. Blockade of \u03b1v\u03b26 and \u03b1v\u03b28 integrins with a chromogranin A-derived peptide inhibits TGF\u03b2 activation in tumors and suppresses tumor growth. J Exp Clin Cancer Res. 2025;44:88. https:\/\/doi.org\/10.1186\/s13046-025-03352-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"16550_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00262-015-1781-6","volume":"65","author":"M Noguchi","year":"2016","unstructured":"Noguchi M, Moriya F, Koga N, et al. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 2016;65:151\u201360. https:\/\/doi.org\/10.1007\/s00262-015-1781-6.","journal-title":"Cancer Immunol Immunother"},{"key":"16550_CR35","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1111\/cas.13397","volume":"108","author":"N Koga","year":"2017","unstructured":"Koga N, Moriya F, Waki K, et al. Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine. Cancer Sci. 2017;108:2326\u201332. https:\/\/doi.org\/10.1111\/cas.13397.","journal-title":"Cancer Sci"},{"key":"16550_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","volume":"6","author":"CE Ariyan","year":"2018","unstructured":"Ariyan CE, Brady MS, Siegelbaum RH, et al. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018;6:189\u2013200. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0356.","journal-title":"Cancer Immunol Res"},{"key":"16550_CR37","doi-asserted-by":"publisher","first-page":"eadf6724","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi W, Wang Y, Zhao Y, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15:eadf6724. https:\/\/doi.org\/10.1126\/scitranslmed.adf6724.","journal-title":"Sci Transl Med"},{"key":"16550_CR38","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/2326-6066.CIR-16-0042","volume":"4","author":"XX Wei","year":"2016","unstructured":"Wei XX, Chan S, Kwek S, et al. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016;4:948\u201358. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0042.","journal-title":"Cancer Immunol Res"},{"key":"16550_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/2326-6066.CIR-16-0037","volume":"4","author":"B Farsaci","year":"2016","unstructured":"Farsaci B, Donahue RN, Grenga I, et al. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunol Res. 2016;4:755\u201365. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0037.","journal-title":"Cancer Immunol Res"},{"key":"16550_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-017-0260-3","volume":"5","author":"LE Johnson","year":"2017","unstructured":"Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. j immunotherapy cancer. 2017;5:56. https:\/\/doi.org\/10.1186\/s40425-017-0260-3.","journal-title":"j immunotherapy cancer"},{"key":"16550_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41391-017-0013-x","volume":"21","author":"Y-C Shen","year":"2018","unstructured":"Shen Y-C, Ghasemzadeh A, Kochel CM, et al. Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer Prostatic Dis. 2018;21:113\u201325. https:\/\/doi.org\/10.1038\/s41391-017-0013-x.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16550_CR42","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.3892\/mmr.2017.6908","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Yang T, Liu L, Lu B. Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity. Mol Med Rep. 2017;16:2868\u201374. https:\/\/doi.org\/10.3892\/mmr.2017.6908.","journal-title":"Mol Med Rep"},{"key":"16550_CR43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1158\/2326-6066.CIR-17-0049","volume":"5","author":"CR Ager","year":"2017","unstructured":"Ager CR, Reilley MJ, Nicholas C, et al. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Cancer Immunol Res. 2017;5:676\u201384. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0049.","journal-title":"Cancer Immunol Res"},{"key":"16550_CR44","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s00262-021-02915-6","volume":"70","author":"K Witt","year":"2021","unstructured":"Witt K, Evans-Axelsson S, Lundqvist A, et al. Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunol Immunother. 2021;70:3155\u201366. https:\/\/doi.org\/10.1007\/s00262-021-02915-6.","journal-title":"Cancer Immunol Immunother"},{"key":"16550_CR45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/pros.22914","volume":"75","author":"L Yan","year":"2015","unstructured":"Yan L, Silva DMD, Verma B, et al. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate. 2015;75:280\u201391. https:\/\/doi.org\/10.1002\/pros.22914.","journal-title":"Prostate"},{"key":"16550_CR46","doi-asserted-by":"publisher","first-page":"18192","DOI":"10.18632\/oncotarget.4145","volume":"6","author":"M Podrazil","year":"2015","unstructured":"Podrazil M, Horvath R, Becht E, et al. Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015;6:18192\u2013205. https:\/\/doi.org\/10.18632\/oncotarget.4145.","journal-title":"Oncotarget"},{"key":"16550_CR47","doi-asserted-by":"publisher","first-page":"e1105431","DOI":"10.1080\/2162402X.2015.1105431","volume":"5","author":"JM Van Dodewaard-de Jong","year":"2016","unstructured":"Van Dodewaard-de Jong JM, Santegoets SJ, Van De Ven PM, et al. Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. OncoImmunology. 2016;5:e1105431. https:\/\/doi.org\/10.1080\/2162402X.2015.1105431.","journal-title":"OncoImmunology"},{"key":"16550_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41391-020-0254-y","volume":"24","author":"Z Yuan","year":"2021","unstructured":"Yuan Z, Fernandez D, Dhillon J, et al. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer Prostatic Dis. 2021;24:140\u20139. https:\/\/doi.org\/10.1038\/s41391-020-0254-y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16550_CR49","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.3389\/ebm.2024.10021","volume":"249","author":"N Zareian","year":"2024","unstructured":"Zareian N, Eremin O, Pandha H, et al. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms. Exp Biol Med. 2024;249:10021. https:\/\/doi.org\/10.3389\/ebm.2024.10021.","journal-title":"Exp Biol Med"},{"key":"16550_CR50","doi-asserted-by":"publisher","first-page":"e005060","DOI":"10.1136\/jitc-2022-005060","volume":"10","author":"HK Potluri","year":"2022","unstructured":"Potluri HK, Ferreira CA, Grudzinski J, et al. Antitumor efficacy of90 Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. J Immunother Cancer. 2022;10:e005060. https:\/\/doi.org\/10.1136\/jitc-2022-005060.","journal-title":"J Immunother Cancer"},{"key":"16550_CR51","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1158\/1078-0432.CCR-24-3693","volume":"31","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Autio KA, Cabanski CR, et al. Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2025;31:1463\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3693.","journal-title":"Clin Cancer Res"},{"key":"16550_CR52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:697\u2013717. https:\/\/doi.org\/10.1038\/s41391-021-00340-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16550_CR53","doi-asserted-by":"publisher","first-page":"1181051","DOI":"10.3389\/fimmu.2023.1181051","volume":"14","author":"M Noori","year":"2023","unstructured":"Noori M, Azizi S, Mahjoubfar A, et al. Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1181051. https:\/\/doi.org\/10.3389\/fimmu.2023.1181051.","journal-title":"Front Immunol"},{"key":"16550_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00432-025-06245-3","volume":"151","author":"R Rosenfeld","year":"2025","unstructured":"Rosenfeld R, Sganga S, Badalamenti M, et al. Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review. J Cancer Res Clin Oncol. 2025;151:195. https:\/\/doi.org\/10.1007\/s00432-025-06245-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"16550_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","volume":"23","author":"L Chen","year":"2024","unstructured":"Chen L, Xu Y-X, Wang Y-S, et al. Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Mol Cancer. 2024;23:229. https:\/\/doi.org\/10.1186\/s12943-024-02137-1.","journal-title":"Mol Cancer"},{"key":"16550_CR56","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","volume":"30","author":"Z Kuang","year":"2023","unstructured":"Kuang Z, Liu X, Zhang N, et al. USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1. Cell Death Differ. 2023;30:2249\u201364. https:\/\/doi.org\/10.1038\/s41418-023-01219-9.","journal-title":"Cell Death Differ"},{"key":"16550_CR57","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","volume":"26","author":"AZ Obradovic","year":"2020","unstructured":"Obradovic AZ, Dallos MC, Zahurak ML, et al. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clin Cancer Res. 2020;26:3182\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3372.","journal-title":"Clin Cancer Res"},{"key":"16550_CR58","doi-asserted-by":"publisher","first-page":"2501542","DOI":"10.1002\/advs.202501542","volume":"12","author":"J Li","year":"2025","unstructured":"Li J, Lv W, Han Z, et al. Mitoxantrone-Encapsulated ZIF\u20108 Enhances Chemo\u2010Immunotherapy via Amplified Immunogenic Cell Death. Adv Sci. 2025;12:2501542. https:\/\/doi.org\/10.1002\/advs.202501542.","journal-title":"Adv Sci"},{"key":"16550_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","volume":"36","author":"W Su","year":"2019","unstructured":"Su W, Han HH, Wang Y, et al. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell. 2019;36:139\u2013e15510. https:\/\/doi.org\/10.1016\/j.ccell.2019.06.009.","journal-title":"Cancer Cell"},{"key":"16550_CR60","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00262-025-04070-8","volume":"74","author":"Z Fan","year":"2025","unstructured":"Fan Z, Wang Z, Zhang H, et al. Extracellular vesicles derived from mature dendritic cells loaded with cDC1-specific chemokine XCL1 combined with chemotherapy-induced ICD for the treatment of castration-resistant prostate cancer. Cancer Immunol Immunother. 2025;74:242. https:\/\/doi.org\/10.1007\/s00262-025-04070-8.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16550-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:03:31Z","timestamp":1792073011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16550-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16550"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16550-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1233"}}